The results of the use of 2-(para-aminobenzenesulfonamido) pyridine, officially known as sulfapyridine, in animal experiments and the favorable effects obtained with it in the treatment of pneumonic infections in human beings warrant a trial of this drug with infants and children under carefully controlled conditions. Furthermore, whenever possible the results of such a study should be subjected to statistical analysis. For this purpose we have employed the methods of Fisher1 because they appeared to be the most appropriate for the analysis of a small series.2 Both the value and the possible harmful effects of sulfapyridine must be determined as soon as possible so that physicians may know how widely it should be used. No attempt will be made to review the literature on this subject, since adequate reviews are available.3
In a study of any treatment of pneumonia in children the low case fatality rate makes it
WILSON AT, SPREEN AH, COOPER ML, STEVENSON FE, CULLEN GE, MITCHELL AG. SULFAPYRIDINE IN THE TREATMENT OF PNEUMONIA IN INFANCY AND CHILDHOOD. JAMA. 1939;112(15):1435–1439. doi:10.1001/jama.1939.02800150007002
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: